COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

被引：73

作者：

Chatzikonstantinou, Thomas ^{[1
,2
,3
]}

Kapetanakis, Anargyros ^{[3
]}

Scarfo, Lydia ^{[4
,5
]}

Karakatsoulis, Georgios ^{[3
,6
]}

Allsup, David ^{[7
]}

Alonso Cabrero, Alejandro ^{[8
,9
]}

Andres, Martin ^{[10
]}

Antic, Darko ^{[11
,12
]}

Baile, Monica ^{[13
]}

Baliakas, Panagiotis ^{[14
,15
]}

Bron, Dominique ^{[16
]}

Capasso, Antonella ^{[17
]}

Chatzileontiadou, Sofia ^{[18
]}

Cordoba, Raul ^{[19
]}

Correa, Juan-Gonzalo ^{[20
]}

Cuellar-Garcia, Carolina ^{[21
]}

De Paoli, Lorenzo ^{[22
]}

De Paolis, Maria Rosaria ^{[23
]}

Del Poeta, Giovanni ^{[24
]}

Demosthenous, Christos ^{[1
,2
]}

Dimou, Maria ^{[25
]}

Donaldson, David ^{[26
]}

Doubek, Michael ^{[27
]}

Efstathopoulou, Maria ^{[28
]}

Eichhorst, Barbara ^{[29
]}

El-Ashwah, Shaimaa ^{[30
]}

Enrico, Alicia ^{[31
]}

Espinet, Blanca ^{[32
]}

Farina, Lucia ^{[33
]}

Ferrari, Angela ^{[34
]}

Foglietta, Myriam ^{[35
]}

Frederiksen, Henrik ^{[36
]}

Furstenau, Moritz ^{[29
]}

Garcia-Marco, Jose A. ^{[37
]}

Garcia-Serra, Rocio ^{[38
,39
]}

Gentile, Massimo ^{[40
]}

Gimeno, Eva ^{[41
]}

Glenthoj, Andreas ^{[42
]}

da Silva, Maria Gomes ^{[43
]}

Gutwein, Odit ^{[44
,45
]}

Hakobyan, Yervand K. ^{[46
]}

Herishanu, Yair ^{[47
,48
]}

Angel Hernandez-Rivas, Jose ^{[49
]}

Herold, Tobias ^{[50
]}

Innocenti, Idanna ^{[51
]}

Itchaki, Gilad ^{[48
,52
]}

Jaksic, Ozren ^{[53
]}

Janssens, Ann ^{[54
]}

Kalashnikova, Olga B. ^{[55
]}

Kalicinska, Elzbieta ^{[56
]}

机构：

[1] G Papanicolaou Hosp, Hematol Dept, Thessaloniki, Greece

[2] G Papanicolaou Hosp, HCT Unit, Thessaloniki, Greece

[3] Ctr Res & Technol Hellas, Inst Appl Biosci, Thessaloniki, Greece

[4] Univ Vita Salute San Raffaele, Milan, Italy

[5] IRCC Osped San Raffaele, Milan, Italy

[6] Univ Ioannina, Dept Math, Ioannina, Greece

[7] Hull York Med Sch, Ctr Atherothrombosis & Metab Dis, Kingston Upon Hull, N Humberside, England

[8] Spanish Soc Haematol & Hemotherapy, Madrid, Spain

[9] Hosp Univ La Princesa, Hematol Dept, Madrid, Spain

[10] Univ Bern, Bern Univ Hosp, Dept Hematol & Cent Hematol Lab, Inselspital, Bern, Switzerland

[11] Univ Clin Ctr Serbia, Belgrade, Serbia

[12] Univ Belgrade, Sch Med, Belgrade, Serbia

[13] Hosp Clin Univ Salamanca CAUSA IBSAL, Salamanca, Spain

[14] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden

[15] Uppsala Univ Hosp, Dept Clin Genet, Uppsala, Sweden

[16] Inst J Bordet ULB, Brussels, Belgium

[17] IRCSS Osped San Raffaele, Milan, Italy

[18] AHEPA Hosp, Dept Internal Med 1, Hematol Unit, AUTH, Thessaloniki, Greece

[19] Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Dept Hematol, Madrid, Spain

[20] Hosp Clin Barcelona, Barcelona, Spain

[21] Terrassa Hosp, Hematol Unit, Terrassa, Spain

[22] Univ Piemonte Orientale Amedeo Avogadro, Azienda Osped Univ Maggiore Carita Novara, Dept Translat Med, Div Hematol, Novara, Italy

[23] PO Vito Fazzi Lecce, UOC Ematol, Lecce, Italy

[24] Univ Tor Vergata, Dept Biomed & Prevent Hematol, Rome, Italy

[25] Natl & Kapodistrian Univ Athens, Internal Med Dept 1, Hematol Clin Trial Unit, Propaedeut, Athens, Greece

[26] Belfast City Hosp, Belfast, Antrim, North Ireland

[27] Masaryk Univ, Univ Hosp, Fac Med, Dept Internal Med Hematol & Oncol,Dept Med Genet, Brno, Czech Republic

[28] Athens Med Ctr, Dept Haematol, Psychikon Branch, Athens, Greece

[29] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med 1, Cologne, Germany

[30] Mansoura Univ, Fac Med, Oncol Ctr, Clin Hematol Unit, Mansoura 35516, Egypt

[31] Hosp Italiano La Plata, Buenos Aires, DF, Argentina

[32] Hosp del Mar, Pathol Serv, Barcelona, Spain

[33] Fdn IRCCS Ist Nazl Tumori, Hematol, Milan, Italy

[34] Azienda Unita Sanitaria Locale IRCCS, Hematol Unit, Reggio Emilia, Italy

[35] AO S Croce & Carle, Div Hematol, Cuneo, Italy

[36] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[37] Hosp Univ Puerta de Hierro Majadahonda, Hematol Dept, Madrid, Spain

[38] Hosp Gen Univ, Dept Hematol, Valencia, Spain

[39] Hosp Gen Univ, Fdn Invest, Valencia, Spain

[40] AO Cosenza, Hematol Unit, Cosenza, Italy

[41] Hosp del Mar, Dept Hematol, Barcelona, Spain

[42] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark

[43] Portuguese Inst Oncol, Hematol Dept, Lisbon, Portugal

[44] Shamir Med Ctr, Dept Hematol, Zerifin, Israel

[45] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[46] Hematol Ctr, Yerevan, Armenia

[47] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[48] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[49] Infanta Leonor Univ Hosp, Hematol Dept, Madrid, Spain

[50] Ludwig Maximilians Univ Munchen, Dept Med 3, Lab Leukemia Diagnost, Univ Hosp, Munich, Germany

来源：

LEUKEMIA | 2021年 / 35卷 / 12期

关键词：

D O I：

10.1038/s41375-021-01450-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

引用

页码：3444 / 3454

页数：11

共 29 条

[1]

American Society of Hematology (ASH), 2021, COVID 19 CLL FREQ AS

[2] Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report [J].

Cuneo, Antonio ;

Scarfo, Lydia ;

Reda, Gianluigi ;

Varettoni, Marzia ;

Quaglia, Francesca Maria ;

Marchetti, Monia ;

De Paoli, Lorenzo ;

Re, Francesca ;

Pietrasanta, Daniela ;

Rigolin, Gian Matteo ;

Orsucci, Lorella ;

Ibatici, Adalberto ;

Gattei, Valter ;

Mauro, Francesca R. ;

Trentin, Livio ;

Laurenti, Luca ;

Marasca, Roberto ;

Foa, Robin .

BLOOD, 2020, 136 (06) :763-766

[3] Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes [J].

England, James T. ;

Abdulla, Alym ;

Biggs, Catherine M. ;

Lee, Agnes Y. Y. ;

Hay, Kevin A. ;

Hoiland, Ryan L. ;

Wellington, Cheryl L. ;

Sekhon, Mypinder ;

Jamal, Shahin ;

Shojania, Kamran ;

Chen, Luke Y. C. .

BLOOD REVIEWS, 2021, 45

[4] Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020 [J].

Finelli, Lyn ;

Gupta, Vikas ;

Petigara, Tanaz ;

Yu, Kalvin ;

Bauer, Karri A. ;

Puzniak, Laura A. .

JAMA NETWORK OPEN, 2021, 4 (04)

[5] Perturbation of the normal immune system in patients with CLL [J].

Forconi, Francesco ;

Moss, Paul .

BLOOD, 2015, 126 (05) :573-581

[6]

Gordon AC, 2021, NEW ENGL J MED, V384, P1491, DOI [10.1056/NEJMc2108482, 10.1056/NEJMoa2100433]

[7] iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillermo ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael ;

Montserrat, Emili ;

Chiorazzi, Nicholas ;

Stilgenbauer, Stephan ;

Rai, Kanti R. ;

Byrd, John C. ;

Eichhorst, Barbara ;

O'Brien, Susan ;

Robak, Tadeusz ;

Seymour, John F. ;

Kipps, Thomas J. .

BLOOD, 2018, 131 (25) :2745-2760

[8] Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis [J].

Harrison, Stephanie L. ;

Fazio-Eynullayeva, Elnara ;

Lane, Deirdre A. ;

Underhill, Paula ;

Lip, Gregory Y. H. .

PLOS MEDICINE, 2020, 17 (09)

[9] COVID-19 in persons with haematological cancers [J].

He, Wenjuan ;

Chen, Lei ;

Chen, Li ;

Yuan, Guolin ;

Fang, Yun ;

Chen, Wenlan ;

Wu, Di ;

Liang, Bo ;

Lu, Xiaoting ;

Ma, Yanling ;

Li, Lei ;

Wang, Hongxiang ;

Chen, Zhichao ;

Li, Qiubai ;

Gale, Robert Peter .

LEUKEMIA, 2020, 34 (06) :1637-1645

[10]

Kassambara A, survminer: Drawing Survival Curves using 'ggplot2'

← 1 2 3 →